

Antje Willuweit

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5614077/antje-willuweit-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43
papers

711
citations

17
h-index

25
g-index

47
ext. papers

841
ext. citations

5.2
avg. IF

3.62
L-index

#	Paper	IF	Citations
43	Post-stroke treatment with argon preserved neurons and attenuated microglia/macrophage activation long-termly in a rat model of transient middle cerebral artery occlusion (tMCAO).. <i>Scientific Reports</i> , 2022 , 12, 691	4.9	
42	CLC anion/proton exchangers regulate secretory vesicle filling and granule exocytosis in chromaffin cells.. <i>Journal of Neuroscience</i> , 2022 ,	6.6	1
41	Comparison of the Amyloid Load in the Brains of Two Transgenic Alzheimer's Disease Mouse Models Quantified by Florbetaben Positron Emission Tomography. <i>Frontiers in Neuroscience</i> , 2021 , 15, 699926	5.1	0
40	A Novel Anti-Inflammatory d-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse Model. <i>Molecules</i> , 2021 , 26,	4.8	3
39	PEA β Triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
38	In Vitro and In Vivo Efficacies of the Linear and the Cyclic Version of an All-d-Enantiomeric Peptide Developed for the Treatment of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
37	Current trends in the use of O-(2-[F]fluoroethyl)-L-tyrosine ([F]FET) in neurooncology. <i>Nuclear Medicine and Biology</i> , 2021 , 92, 78-84	2.1	11
36	Sex-Related Motor Deficits in the Tau-P301L Mouse Model. <i>Biomedicines</i> , 2021 , 9,	4.8	2
35	Predicting experimental success: a retrospective case-control study using the rat intraluminal thread model of stroke. <i>DMM Disease Models and Mechanisms</i> , 2020 , 13,	4.1	1
34	Investigation of Cerebral O-(2-[F]Fluoroethyl)-L-Tyrosine Uptake in Rat Epilepsy Models. <i>Molecular Imaging and Biology</i> , 2020 , 22, 1255-1265	3.8	2
33	Safety and pharmacokinetics of the orally available antiprionic compound PRI-002: A single and multiple ascending dose phase I study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020 , 6, e12001	6	12
32	High uptake of Ga-PSMA and F-DCFPyL in the peritumoral area of rat gliomas due to activated astrocytes. <i>EJNMMI Research</i> , 2020 , 10, 55	3.6	7
31	Post-stroke treatment with argon attenuated brain injury, reduced brain inflammation and enhanced M2 microglia/macrophage polarization: a randomized controlled animal study. <i>Critical Care</i> , 2019 , 23, 198	10.8	24
30	Treatment-Related Uptake of -(2-F-Fluoroethyl)-l-Tyrosine and l-[Methyl-H]-Methionine After Tumor Resection in Rat Glioma Models. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 1373-1379	8.9	4
29	A β Oligomer Elimination Restores Cognition in Transgenic Alzheimer's Mice with Full-blown Pathology. <i>Molecular Neurobiology</i> , 2019 , 56, 2211-2223	6.2	18
28	O-(2-[18F]-Fluoroethyl)-L-Tyrosine (FET) in Neurooncology: A Review of Experimental Results. <i>Current Radiopharmaceuticals</i> , 2019 , 12, 201-210	1.8	8
27	Cis-4-[18F]fluoro-D-proline detects neurodegeneration in patients with akinetic-rigid parkinsonism. <i>Nuclear Medicine Communications</i> , 2019 , 40, 383-387	1.6	1

26	Deceleration of the neurodegenerative phenotype in pyroglutamate-A β accumulating transgenic mice by oral treatment with the A β oligomer eliminating compound RD2. <i>Neurobiology of Disease</i> , 2019 , 124, 36-45	7.5	8
25	Osteopontin Attenuates Secondary Neurodegeneration in the Thalamus after Experimental Stroke. <i>Journal of NeuroImmune Pharmacology</i> , 2019 , 14, 295-311	6.9	11
24	Investigation of cis-4-[F]Fluoro-D-Proline Uptake in Human Brain Tumors After Multimodal Treatment. <i>Molecular Imaging and Biology</i> , 2018 , 20, 1035-1043	3.8	4
23	Comprehensive Characterization of the Pyroglutamate Amyloid- β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice. <i>Journal of Alzheimer's Disease</i> , 2018 , 63, 115-130	4.3	6
22	In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, 859-873	4.3	8
21	Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease. <i>European Journal of Pharmaceutical Sciences</i> , 2018 , 114, 93-102	5.1	11
20	Design and use of a folded four-ring double-tuned birdcage coil for rat brain sodium imaging at 9.4 T. <i>Journal of Magnetic Resonance</i> , 2018 , 286, 110-114	3	8
19	A β oligomer eliminating compounds interfere successfully with pEA β (42) induced motor neurodegenerative phenotype in transgenic mice. <i>Neuropeptides</i> , 2018 , 67, 27-35	3.3	7
18	Influence of Bevacizumab on Blood-Brain Barrier Permeability and -(2-F-Fluoroethyl)-L-Tyrosine Uptake in Rat Gliomas. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 700-705	8.9	23
17	Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[F]fluoroethyl)-L-tyrosine (FET). <i>Methods</i> , 2017 , 130, 124-134	4.6	55
16	Osteopontin Augments M2 Microglia Response and Separates M1- and M2-Polarized Microglial Activation in Permanent Focal Cerebral Ischemia. <i>Mediators of Inflammation</i> , 2017 , 2017, 7189421	4.3	25
15	Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease. <i>Molecules</i> , 2017 , 22,	4.8	17
14	The A β oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology. <i>Scientific Reports</i> , 2017 , 7, 16275	4.9	28
13	Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by 18F-Fluoroethyl-L-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 129-137	8.9	34
12	Influence of blood-brain barrier permeability on O-(2-F-fluoroethyl)-L-tyrosine uptake in rat gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 408-416	8.8	18
11	Pharmacokinetic Properties of a Novel D-Peptide Developed to be Therapeutically Active Against Toxic β Amyloid Oligomers. <i>Pharmaceutical Research</i> , 2016 , 33, 328-36	4.5	28
10	Blood-brain barrier penetration of an A β targeted, arginine-rich, d-enantiomeric peptide. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2016 , 1858, 2717-2724	3.8	15
9	Reproducibility of O-(2-(18)F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1115-23	8.8	15

8	Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer's disease. <i>European Journal of Pharmaceutical Sciences</i> , 2016 , 89, 31-8	5.1	20
7	QIAD assay for quantitating a compound's efficacy in elimination of toxic A β oligomers. <i>Scientific Reports</i> , 2015 , 5, 13222	4.9	33
6	Osteopontin mediates survival, proliferation and migration of neural stem cells through the chemokine receptor CXCR4. <i>Stem Cell Research and Therapy</i> , 2015 , 6, 99	8.3	53
5	Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer's Disease. <i>PLoS ONE</i> , 2015 , 10, e0128553	3.7	22
4	Uptake of O-(2-[¹⁸ F]fluoroethyl)-L-tyrosine in reactive astrocytosis in the vicinity of cerebral gliomas. <i>Nuclear Medicine and Biology</i> , 2013 , 40, 795-800	2.1	21
3	Detection of remote neuronal reactions in the Thalamus and Hippocampus induced by rat glioma using the PET tracer cis-4-[¹¹ C]fluoro-D-proline. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013 , 33, 724-31	7.3	8
2	Small-animal PET imaging of amyloid-beta plaques with [¹¹ C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. <i>PLoS ONE</i> , 2012 , 7, e31310	3.7	94
1	Early-onset and robust amyloid pathology in a new homozygous mouse model of Alzheimer's disease. <i>PLoS ONE</i> , 2009 , 4, e7931	3.7	36